Artemisinin Resistance in Plasmodium falciparum Malaria
By A. Dondorp, Francois Nosten, P. Yi, D. Das, A. P. Phyo, J. Tarning, K. Lwin., F. Ariey, Warunee Hanpithakpong, Sue J Lee and 13 more. New England Journal of Medicine, 2009
3,357 citations recorded by the source corpus.
BACKGROUND Artemisinin-based combination therapies are the recommended first-line treatments of falciparum malaria in all countries with endemic disease. There are recent concerns that the efficacy of such therapies has declined on the Thai–Cambodian border, historically a site of emerging antimalarial-drug resistance. METHODS In two open-label, randomized trials, we compared the efficacies of two treatments for uncomplicated falciparum malaria in Pailin, western Cambodia, and Wang Pha, northwestern Thailand: oral artesunate given at a dose of 2 mg per kilogram of body weight per day, for 7 days, and artesunate given at a dose of 4 mg per kilogram per day, for 3 days, followed by mefloquine at two doses totaling 25 mg per kilogram. We assessed in vitro and in vivo Plasmodium falciparum susceptibility, artesunate pharmacokinetics, and molecular markers of resistance. RESULTS We studied 40 patients in each of the two locations. The overall median parasite clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours (interquartile range, 36 to 66) in Wang Pha (P<0.001). Recrudescence confirmed by means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiving artesunate monotherapy and 1 of 20 (5%) receiving artesunate–mefloquine therapy in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), respectively, in Wang Pha (P = 0.31). These markedly different parasitologic responses were not explained by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of isotopic in vitro sensitivity tests, or putative molecular correlates of P. falciparum drug resistance (mutations or amplifications of the gene encoding a multidrug resistance protein [PfMDR1] or mutations in the gene encoding sarco–endoplasmic reticulum calcium ATPase6 [PfSERCA]). Adverse events were mild and did not differ significantly between the two treatment groups. CONCLUSIONS P. falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand. Resistance is characterized by slow parasite clearance in vivo without corresponding reductions on conventional in vitro susceptibility testing. Containment measures are urgently needed. (ClinicalTrials.gov number, NCT00493363, and Current Controlled Trials number, ISRCTN64835265.)
Subfields: Cell Biology, Hematology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/74414d7048aac6756b0b5d949c4d124ce46e8a14
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Public Health, Environmental and Occupational Health
Citations in the corpus
- A molecular marker of artemisinin-resistant Plasmodium falciparum malaria (2013, methodology): “K13-propeller polymorphism fulfils the definition of a molecular marker of ART resistance for several reasons: (1) there has been a progressive loss of wild-type parasites in western Cambodia during the decade of emerging ART resistance in this region; (2) mutant parasites cluster in Cambodian provi”
- Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies (2010, background): “The recent emergence of partial drug resistance to artemisinin in Cambodia [90] has further highlighted the need to guard against and reduce the emergence and spread of resistance, particularly as access to treatment is scaled up.”
- Malaria: Biology and Disease. (2016, positive): “clearance times after monotherapy (Dondorp et al., 2009; Noedl et al., 2008) and this has developed further into decreasing clinical efficacy (Ashley et al.”
- A Research Agenda to Underpin Malaria Eradication (2011, positive): “potential new drugs for first-line treatment [9,10].”
- Into the Eye of the Cytokine Storm (2012, background): “The majority of antimalarial drugs sold in Africa are either ineffective or accelerate malarial parasite resistance owing to the distribution of counterfeit drugs (9, 43).”